Previous studies have shown that patients receiving PD-1 inhibitors are at higher risk for thyroid disease, particularly when thyroid antibodies (TPOAb and TgAb) are present either at baseline or develop during treatment (2). The gene discussed is PDCD1; the disease is thyroiditis.